Rebastinib

CAS: 1020172-07-9

Ref. TR-R139300

Product Information

• Name: Rebastinib
• Synonyms: DCC-2036, DP 1919, 4-[4-[(5-tert-Butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide, N-[3-tert-Butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl]-N'-[2-fluoro-4-[(2-(methylcarbamoyl)pyridin-4-yl)oxy]phenyl]urea, Dcc-2036
• CAS: 1020172-07-9

Description

Applications Rebastinib shows the selectivity for growth inhibition of Bcr-Abl-positive cells by its marked inhibition of CML cell lines compared to non-CML leukemia lines. Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1. It is a COVID19-related research product.
References Eide, C., et al.: Cancer Res., 71, 3189 (2011)

• Brand: TRC

Chemical properties

• Molecular weight: 553.59
• Formula: C₃₀H₂₈FN₇O₃
• Color/Form: Off-White Solid
• InChI: InChI=1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17H,1-4H3,(H,32,39)(H2,35,36,40)
• InChI key: InChIKey=WVXNSAVVKYZVOE-UHFFFAOYSA-N
• SMILES: CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1